Search hospitals > Minnesota > Burnsville
Minnesota Oncology - Burnsville
Claim this profileBurnsville, Minnesota 55337
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Lung Cancer
Conducts research for Stomach Cancer
130 reported clinical trials
10 medical researchers
Summary
Minnesota Oncology - Burnsville is a medical facility located in Burnsville, Minnesota. This center is recognized for care of Skin Cancer, Breast Cancer, Cancer, Lung Cancer, Stomach Cancer and other specialties. Minnesota Oncology - Burnsville is involved with conducting 130 clinical trials across 305 conditions. There are 10 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 positive
HER2 negative
ER positive
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park8 years of reported clinical research
Expert in Skin Cancer
Expert in Non-Small Cell Lung Cancer
104 reported clinical trials
167 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital6 years of reported clinical research
Expert in Skin Cancer
Expert in Cancer
61 reported clinical trials
110 drugs studied
Yan JiRegions Hospital1 year of reported clinical research
Studies Breast Cancer
Studies Skin Cancer
32 reported clinical trials
77 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park6 years of reported clinical research
Studies Cancer
Studies Uterine Tumors
14 reported clinical trials
19 drugs studied
Clinical Trials running at Minnesota Oncology - Burnsville
Breast Cancer
Lung Cancer
Skin Cancer
Breast cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Prostate Cancer
Multiple Myeloma
Ovarian Cancer
Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Minnesota Oncology - Burnsville?
Minnesota Oncology - Burnsville is a medical facility located in Burnsville, Minnesota. This center is recognized for care of Skin Cancer, Breast Cancer, Cancer, Lung Cancer, Stomach Cancer and other specialties. Minnesota Oncology - Burnsville is involved with conducting 130 clinical trials across 305 conditions. There are 10 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.